Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Sotatercept reversed vascular remodeling in patients with PAH

Key clinical point: Sotatercept decreased PVR and improved 6-minute walk time vs. placebo.

Major finding: PVR declined by 20.5% to 33.9% with sotatercept over 24 weeks of treatment.

Study details: Randomized, double blind, placebo-controlled phase 2 study of 106 patients with pulmonary arterial hypertension.

Disclosures: The study was supported by Acceleron Pharma. Dr. Badesch disclosed research support from and consulting/advising for the company and others. Dr. Kawut has disclosed grants from several companies and travel support from ATS and the Pulmonary Hypertension Association.